MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Waters Corporation DPO Ratio 2011-2026 | WAT
Annual DPO Ratio Waters Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 96.7 | 102 | 61.1 | 87.9 | 22 | 17.7 | 25.1 | 24.9 | 27.7 | 30.6 | 29.1 | 30.3 | 27.1 | 27.6 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 102 | 17.7 | 43.5 |
Quarterly DPO Ratio Waters Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 59.4 | 55.5 | 60.5 | - | - | - | - | - | - | - | - | - | - | - | - | 24.1 | 29 | 26.8 | 27.6 | 20.6 | 25.1 | 30.9 | 26.2 | 14.9 | 18.6 | 17.9 | 24.2 | 21.7 | 25.8 | 25.6 | 27.3 | 21.8 | 25 | 25.6 | 28.6 | 24.6 | 28.3 | 28.1 | 31.4 | 27.1 | 31.1 | 30.9 | 32.9 | 25.7 | 29.6 | 29.7 | 31.8 | 25.9 | 30.9 | 31.5 | 31.3 | 24 | 27.3 | 27.9 | 30 | 24.7 | 28 | 28.7 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 60.5 | 14.9 | 28.8 |
DPO Ratio of other stocks in the Diagnostics research industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
120 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Anixa Biosciences
ANIX
|
1.29 K | $ 3.01 | -2.9 % | $ 97.7 K |  USA |
|
Akumin
AKU
|
21.3 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
112 | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
56.3 | - | -13.05 % | $ 7.29 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
125 | $ 33.99 | 0.65 % | $ 366 M |  China |
 |
Accelerate Diagnostics
AXDX
|
125 | - | -61.36 % | $ 2.46 M | USA |
 |
BioNano Genomics
BNGO
|
104 | $ 1.38 | -6.12 % | $ 1.75 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
45.8 | - | - | $ 562 M |  Britain |
 |
Castle Biosciences
CSTL
|
52 | $ 39.01 | -0.38 % | $ 1.08 B | USA |
 |
Chembio Diagnostics
CEMI
|
52.5 | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
106 | - | - | $ 79.8 M | USA |
 |
Danaher Corporation
DHR
|
66.4 | $ 218.94 | -0.24 % | $ 160 B | USA |
 |
Exact Sciences Corporation
EXAS
|
139 | $ 102.48 | 0.18 % | $ 19 B | USA |
 |
DermTech
DMTK
|
47.4 | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
17.7 | - | - | $ 399 M | China |
 |
Fulgent Genetics
FLGT
|
34.9 | $ 26.01 | -0.88 % | $ 786 M | USA |
 |
Fluidigm Corporation
FLDM
|
61.4 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
780 | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
43.5 | - | 0.12 % | $ 80.1 M | China |
 |
Guardant Health
GH
|
83.6 | $ 111.89 | 1.28 % | $ 13.7 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
8.98 | - | - | $ 10.7 B | USA |
 |
DexCom
DXCM
|
70.4 | $ 73.26 | -1.0 % | $ 28.3 B | USA |
 |
CareDx, Inc
CDNA
|
44.2 | $ 20.4 | -1.92 % | $ 1.1 B | USA |
 |
DarioHealth Corp.
DRIO
|
43.9 | $ 10.95 | 6.31 % | $ 311 M |  Israel |
 |
Enzo Biochem
ENZ
|
52.3 | - | -8.98 % | $ 14.8 K | USA |
 |
Lantheus Holdings
LNTH
|
25.3 | $ 65.82 | -1.3 % | $ 4.55 B | USA |
 |
Heska Corporation
HSKA
|
39.7 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
112 | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
56.3 | $ 145.95 | -2.5 % | $ 23.2 B | USA |
 |
QIAGEN N.V.
QGEN
|
50 | - | - | $ 10.6 B |  Niderland |
 |
IQVIA Holdings
IQV
|
126 | $ 230.03 | -2.31 % | $ 41.7 B | USA |
 |
NeoGenomics
NEO
|
20.7 | $ 11.85 | -4.44 % | $ 1.5 B | USA |
 |
Charles River Laboratories International
CRL
|
24.5 | $ 210.0 | -0.83 % | $ 10.8 B | USA |
 |
Medpace Holdings
MEDP
|
13.3 | $ 583.39 | -1.63 % | $ 18.1 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
18.3 | $ 184.82 | 1.37 % | $ 20.5 B | USA |
 |
Personalis
PSNL
|
67.3 | $ 9.4 | -5.72 % | $ 557 M | USA |
 |
Motus GI Holdings
MOTS
|
1.72 | - | -34.28 % | $ 263 K | Israel |
 |
Precipio
PRPO
|
53 | $ 24.39 | 0.54 % | $ 31.7 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
33.1 | $ 269.39 | -0.16 % | $ 22.6 B | USA |
 |
Mettler-Toledo International
MTD
|
53.4 | $ 1 384.16 | -0.62 % | $ 29.4 B |  Schweiz |
 |
ICON Public Limited Company
ICLR
|
6.52 | $ 179.07 | -3.67 % | $ 14.8 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
27 | $ 674.78 | -0.29 % | $ 55.6 B | USA |
 |
Agilent Technologies
A
|
50.1 | $ 132.75 | -0.37 % | $ 40.4 B | USA |
 |
Biomerica
BMRA
|
32.4 | $ 2.39 | 0.21 % | $ 5.49 M | USA |